**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 65-year-old man developed thrombotic thrombocytopenia purpura (TTP) during treatment with hydroxychloroquine for suspected SARS-CoV-2 infection.

The man, who had chronic obstructive pulmonary disease, was admitted cough, chest and back pain. His nasal swap was obtained for SARS-CoV-2 polymerase chain reaction (PCR). In outpatient setting, he started receiving hydroxychloroquine without waiting for the test results. His SARS-CoV-2 PCR test result was negative. Lab tests showed haemoglobin of 10.8 g/dL, platelets of 31 000/µL, lactate dehydrogenase of 1281 U/L and creatinine of 1.7 g/dL. He had aphasia. He was hospitalised with the suspicion of thrombotic thrombocytopenia purpura (TTP). There was 10% schistocytes in peripheral blood smear. PLASMIC score was 6, which was indicating high probability of TTP.

Hydroxychloroquine was ceased and the man underwent exchange plasmapheresis. He was also treated with methylprednisolone and folic acid. On day 4 of his admission, thrombocytopenia was improved and LDH level had normalised. On day 7, plasmapheresis was discontinued.
